Izotropic Corporation WKN: A2JNLV ISIN: CA46604F1099 Kürzel: IZO Forum: Aktien Thema: Hauptdiskussion

Was passiert mit der izo aktie wenn Siemens es aufkaufen sollte?

Auf jeden Fall nachvollziehbar. In jedem Krankenhaus stehen CT und MRT von Siemens.

Ich verstehe es nicht ganz. Siemens überlegt izo aufzukaufen?

Sehr interessant 👍

Vielen Dank für den Beitrag !!!

Bin noch auf einen interessanten Ansatz gestoßen. Einfach mal durchlesen. Post# 31421428 I didn't write this @Fischlaender off another board, WOW DISCLAIMER: all imho!!! Here is why I think $IZO will be bought out by Siemens, a possible explanation for the recent share performance. I have been in IZO for quite a while, stayed on board and added also in the doldrums when the stock to me unexpectedly underperformed despite encouraging corporate developments earlier this year. There had been some funny marketing groups involved, especially the trading on the German stock market was a bit odd with days of millions and millions being traded whereas CSE volumes were low. Then suddenly trading on the German market more or less seized and as of early July the stock started to climb nicely and gradually. All of a sudden on 31 July it went parabolic. And no news visible. So I scanned the market, nada on IZO. Then I looked on and came across the Varian – Siemens deal, Siemens buying Varian for 16.4 billion USD. Varian is a world leader in tech cancer detection and treatment, especially CT. Siemens is the biggest player in mammography and explicitly bought Varian to strengthen the CT arm. That was released on 2 August, whereas IZO started to climb just the Friday before the weekend takeover announcement. Then I scanned all publicly available IZO documents for Varian and guess what… Two of the main patents that we have from UC Davies concerning the technology for the 3d CT scan are co-owned UC Davies – Varian!!! We bought UC Davies undivided interest but we are in the boat with Varian, see also the 22 February 2018 SEDAR filing concerning the licencing agreement pages 8/9 https://www.sedar.com/GetFile.do?lang=EN&docClass=36&issuerNo=00044761&issuerType=03&projectNo=02731890&docId=4263543 . “Whereas, certain Patent Rights referenced as UC Case No. 2006-740 are jointly-owned with the VARIAN Medical Systems, Inc. (“Varian”), who may license its undivided interest separately, and The Regents has the right to license The Regents’ undivided interest in such jointly-owned Patent Rights exclusively to Licensee subject to the terms and conditions herein; Whereas, VARIAN controls the patent prosecution under a Power of Attorney at the U.S. Patent and Trademark Office (“USPTO”) for the Patent Rights referenced as UC Case No. 2006-740; however, The Regents, as a joint owner of such Patent Rights, is paying for the maintenance fees at the USPTO…” You can then google the underlying patent, it is https://patents.google.com/patent/US20070269000 IZO’s Principal Founder and Director, researcher John Boone gave a PPT 2014 where Varian is also explicitly mentioned, they had probably co-funded some of Boone’s research in return for a share of the patent: https://www.aapm.org/meetings/amos2/pdf/42-11896-45050-565.pdf De facto, if the Siemens – Varian deal closes IZO will be co-owner of the key tech with Siemens. I would not be surprised to see that being revealed big time soon or that we get some buyout offer before IZO gets too expensive.

Hab jetzt bei 41cent für 2k eingekauft, Tageshoch war bei 0,52 wenn sich die Aktie weiterhin so bewegt dann kann man mit alle 2 Wochen 10cent plus aufstieg rechnen

Oh Mann. Ich will auch dringend wieder einsteigen. Allerdings ist der Kurs schon ganz schön hochgegangen. Man weiß aber nicht, ob der noch jemals wieder runterkommt🤔

💲💲💲😂💲💲💲

Join Now Search Companies, etc News Press Releases Izotropic Files Pre-Submission Application with U.S. FDA 3 hours ago Vancouver, British Columbia--(Newsfile Corp. - August 18, 2020) - Izotropic Corporation (CSE: IZO) (OTC Pink: IZOZF) (FSE: 1R3) ("Izotropic" or the "Company") is pleased to announce that it has filed a Pre-Submission Application with the U.S. Food and Drug Administration (FDA) marking the beginning of the market approval process for the Company's commercial Breast CT Imaging System. The Pre-Submission Application filing has been a highly anticipated event for the Company and is a major milestone for the inventors, stakeholders and advocates for breast CT and women's health. Principal Founder and Company Director, Dr. John Boone; Company FDA Consultant, Dr. Anita Nosratieh; and Company Executive VP of Commercial Operations, Dr. John McGraw provided comments on the filing: Dr. John Boone: "I have been working on the development of breast CT for over 20 years; we scanned the first patient using cone beam breast CT in 2004, scanned the first cancer patient in early 2005, and performed the first contrast-enhanced breast CT exam in 2006. It is so satisfying to see this exciting first step towards having our breast CT technology become a clinical reality. I take my cues from the breast imaging radiologists that I have worked with for decades, as they feel that breast CT images will indeed have an important role to play in breast cancer imaging. I am simply thrilled to be a part of this team." Dr. Anita Nosratieh: "The pre-submission process is a mechanism to obtain feedback on both clinical and non-clinical testing needed to support market approval, ensuring the most efficient path forward. For the Company, this means not wasting any time or resources on studies that will not generate the evidence needed to demonstrate safety and effectiveness. I am passionate about advancing women's health and received my doctoral training under John Boone before I joined the U.S. FDA to regulate these types of products. Now to be directly involved in helping this become a reality that will benefit many women is not only a privilege but also a personal dream come true." Dr. John McGraw: "It's been my experience that early engagement with regulatory agencies such as the FDA helps companies move smoothly and efficiently through the regulatory process and Izotropic has the team to drive and manage the process. This filing is a critical step for the Company and will help to accelerate corporate activities and provides confidence to customers and stakeholders that the management team can achieve our objectives as scheduled." The Company believes Breast CT will become a prominent and widely adopted imaging modality in the years to come and it looks forward to working with the FDA and completing the application process, in order to expedite patient access to its Breast CT Imaging System. The Company will continue to announce updates to keep its shareholders informed as to its progress and timelines towards the pre-submission meeting, FDA approval processes and US payor adoption of its Breast CT Imaging System. ON BEHALF OF THE BOARD Robert Thast Chief Executive Officer

Warte seit 2 Wochen dass die Aktie um die 20-30 cent Marke kommt sodass ich nachkaufen kann, aber zurzeit bereue ich es weil ich nicht früher eingekauft habe...

https://www.thenewswire.com/press-releases?id=1Bz4FRoqJ

Natürlich ist es das System super und hat Potential. Dennoch ist der Kurs zu schnell gestiegen...

Und die News sind im Prinzip schon auf deren Homepage. Gibt's als PDF seit einer Weile. Der Weg ist noch lang aber geht dezent nach oben.

Rücksetzer werden hier nur zum Teil stattfinden. Die Firma wird in Zukunft CT Scanner für mehrere 100tsd Dollar verkaufen. Die Technik ist überragend und auf 2 Jahre werden wir hier mehrere Euro pro Aktie sehen denke ich. FDA approval kommt ja auch noch.

Es wundert mich nur, dass noch keine Rücksetzer gekommen sind. Bei der Steigerung...